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SUMMARY
Background
Patients on maintenance dialysis typically show a suboptimal immune response
to hepatitis B virus vaccine compared with the non-uraemic population. A variety
of inherited or acquired factors have been implicated in this diminished response.
It is well known that patients with diabetes mellitus have a compromised
immune system, and diabetic nephropathy is an important cause of chronic kid-
ney disease. However, the impact of diabetes mellitus on the immune response to
HBV vaccine in patients receiving long-term dialysis remains unclear.
Aim
To evaluate the inﬂuence of diabetes mellitus on the immune response to HBV
vaccine in dialysis population by performing a systematic review of the literature
with a meta-analysis of clinical studies.
Methods
We used the random effects model of DerSimonian and Laird with heterogeneity
and sensitivity analyses. The end-point of interest was the rate of patients show-
ing seroprotective antibody against hepatitis B surface antigen at completion of
vaccine schedule in the diabetic vs. the nondiabetic dialysis individuals.
Results
We identiﬁed 12 studies involving 1002 unique patients on long-term dialysis.
Aggregation of study results showed a signiﬁcant decrease in response rates
among the diabetic vs. the nondiabetic patients [pooled odds ratio = 0.52 (95%
CI 0.38–0.71)]. The P-value was 0.29 for our test of study heterogeneity. Stratiﬁed
analysis in various subgroups of interest did not meaningfully change our results.
Conclusions
Our meta-analysis showed a clear association between diabetes mellitus and
impaired response to hepatitis B virus vaccine in individuals on long-term dialy-
sis. Such a relationship is biologically plausible. Vaccination schedules with
adapted vaccine doses and frequent serum testing for loss of immunity against
hepatitis B virus should be considered in patients on maintenance dialysis with
diabetes mellitus.
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INTRODUCTION
The frequency of hepatitis B virus (HBV) infection, as
detected by persistent positivity for hepatitis B surface
antigen in serum, is low but not negligible among
patients with chronic kidney disease (CKD) on mainte-
nance dialysis in the industrialised world.1 In 2002, the
Centers for Disease Control and Prevention (CDC,
Atlanta, GA, USA) has reported that the prevalence of
HBsAg seropositivity among dialysis patients was 1% in
the US.2 Also, outbreaks of HBV infection in haemodial-
ysis (HD) units continue to occur.3 Prevalence and inci-
dence rates of HBV infection remain much higher
within dialysis units in less-developed countries.4 It is
well known that patients undergoing long-term dialysis
have a lower response to HBV vaccine compared with
the non-uraemic population: the number of patients who
develop protective antibody (anti-HBs) against HBV sur-
face antigen (HBsAg) is lower, the antibody titres of
those who mount an antibody response are reduced and
decline faster over time.5
Diabetic patients have a compromised immune system
and their immunological response to HBV vaccine is less
optimal than nondiabetic individuals;6 nevertheless, the
inﬂuence of this metabolic disease on seroprotection rate
after HBV vaccination is not well investigated in chronic
dialysis patients. A few studies on HBV vaccination of
patients with CKD and diabetes mellitus have been pub-
lished and preliminary results have been given.7
The goal of this study was to investigate the avail-
able evidence on the relationship between diabetes mell-
itus and immune response to HBV vaccination in long-
term dialysis population by performing a systematic
review of the literature with a meta-analysis of clinical
studies.
MATERIAL AND METHODS
Search strategy and data extraction
We performed electronic searches of the National
Library of Medicine’s MEDLINE database, Current Con-
tents and manual searches of selected speciality journals
to identify all pertinent literature. It has previously dem-
onstrated that an electronic search alone may not sensi-
tive enough. Four MEDLINE database engines (Ovid,
PubMed, Embase and GratefulMed) were used. The key
words ‘hepatitis B’, ‘vaccine’, ‘diabetes mellitus’, ‘dialysis’
and ‘chronic kidney disease’ were used. Reference lists
from qualitative topic reviews and published clinical tri-
als were also searched. Our search was limited to human
studies that involved individuals aged >19 years
published in the English literature. All articles were iden-
tiﬁed by a search from 1980 to November 2010. Data
extraction was conducted independently by two investi-
gators (F.F., V.D.) and consensus was achieved for all
data. Studies were compared to eliminate duplicate
reports for the same patients, which included contact
with investigators when necessary. Eligibility and exclu-
sion criteria were prespeciﬁed.
Criteria for inclusion
We included studies evaluating only patients undergoing
maintenance hemodialysis (HD) and peritoneal dialysis
(PD). Studies that restricted to students, military recruits
or other cohorts that involved subjects <19 years of age
were excluded. Many studies have identiﬁed an effect of
diabetes mellitus on response rate to HBV vaccine. How-
ever, only studies that (i) speciﬁed either a relative risk
and a measure of variance for vaccine response among
dialysis patients with diabetes mellitus, compared with
nondiabetic individuals, or (ii) presented data in a form
that could be used to construct a 2 · 2 contingency table
were considered for ﬁnal inclusion. Both randomised
controlled trials and observational studies were consid-
ered eligible for inclusion in the analysis. We included
trials using plasma-derived or recombinant DNA hepati-
tis B vaccine. Patients who underwent primary vaccina-
tion schedule (naı¨ve patients) or those who had failed to
respond to prior vaccine schedule (nonresponder
patients) against HBV vaccine were enrolled.
The decision as to inclusion or exclusion of clinical
trials was not related to results. All dose schedules and
routes of administration were included, as long as they
involved primary vaccination regimens and not booster
doses only.
Ineligible studies
Studies were excluded if they reported inadequate data
on measures of response, or included individuals with
positive serology for HBsAg, antibodies to HBsAg
(HBsAb) or human immunodeﬁciency virus (HIV). Tri-
als that were only published as abstracts or as interim
reports were excluded; letters and review articles were
not considered for this analysis. Trials that involved
renal transplant recipients or patients with kidney failure
at predialysis stage were excluded.
End-points of interest
We compared the seroprotection rate after completion of
HBV vaccination schedule in patients with diabetes mell-
itus vs. nondiabetic patients. Patients vaccinated against
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HBV are considered immune if protective titres of anti-
HBs antibody can be demonstrated after completion of
vaccination. The level of antibody production that
deﬁnes seroprotection was 10 IU ⁄mL across the studies.
These deﬁnitions were consistent with standards pub-
lished in the scientiﬁc literature.
Statistical methods
In all studies included in this analysis, data from patients
who did not complete the vaccination schedule were
excluded from the ﬁnal analysis; thus, analysis was made
by per-protocol (PP), not by intention-to-treat (ITT). A
summary estimate of the odds ratio (OR) for serore-
sponse after vaccination among diabetic vs. nondiabetic
patients was generated by use of a random-effects
approach, as described by DerSimonian and Laird.8 The
Cochrane’s Q test was used for quantifying the hetero-
geneity;9 the I2 index – the percentage of total variation
across studies due to heterogeneity rather than chance,10
was also used. The Galbraith plot was made to assess the
heterogeneity and precision of single studies.11 Pooled
ORs were calculated in the subgroups of clinical trials as
sensitivity analyses. The publication bias assessment
(PBA), i.e. the number of void or negative trials neces-
sary to render the meta-analysis meaningless, was made
according to the Klein formula.12 The publication bias
was also measured by the test of funnel plot asymmetry.
The 5% signiﬁcance levels were used for alpha risk.
Every estimate was given with its 95% conﬁdence inter-
vals (95% CI).
RESULTS
Literature review
Our electronic and manual searches identiﬁed 143 manu-
scripts, which were selected for full text review. One
hundred and thirty-one (92%) studies were excluded
because they did not fulﬁl the inclusion criteria. A list of
the 143 bibliographic references is available from the
authors on request. Twelve (8%) articles,13–24 represent-
ing a total of 1002 unique patients, were included in our
meta-analysis. There was a 100% concordance between
reviewers with respect to ﬁnal inclusion and exclusion of
studies reviewed based on the predeﬁned inclusion and
exclusion criteria.
Patient characteristics
Some salient demographic characteristics of subjects
enrolled in the included clinical trials are shown in
Table 1. Many (six of 12, 50%) studies were from centres
in developed world (western Europe and North Amer-
ica). There were two (17%) controlled randomised clini-
cal trials (RCTs), and one clinical controlled trial (CCT).
Nine were cohort studies, three (20%) having retrospec-
tive design.
As listed in Table 2, recombinant HBV vaccine was
used in all clinical studies. Intramuscular administration
of HBV vaccine was used in the majority of patients
(984, 98%). The mean age of subject cohorts ranged
from 43 to 66 years (Table 3). The gender distribution
ranged from 35% to 64% male. All clinical studies
included patients on maintenance dialysis; 917 (92%)
and 85 (8%) underwent regular HD and PD, respectively.
All PD patients received continuous ambulatory perito-
neal dialysis (CAPD).
Summary estimates of outcome
A signiﬁcant decrease in response rates among patients
with diabetes mellitus vs. nondiabetic patients was found;
the pooled OR was = 0.52 (95% CI 0.38–0.71), P = 0.001
according to a random effects model. No signiﬁcant
heterogeneity occurred (P = 0.295). The publication bias
assessment (PBA) was 41. The test of funnel plot asym-
metry was not signiﬁcant [alpha = 0.53; 95% CI, )2.98;
4.05 (P = 0.77)]. The comparison between patients with
DM and nondiabetic patients has been shown in the
Galbraith plot (Figure 1); it provides information on the
heterogeneity between trials. It also reports the effect of
treatment, the precision and the effect of each single trial
included in the meta-analysis.
Table 1 | Baseline characteristics of studies included in
the analysis
Authors
(reference number) Country
Patients,
n
Publication
year
Waite et al.13 Canada 77 1995
Fabrizi et al.14 Italy 118 1996
Mettang et al.15 Germany 32 1996
Jha et al.16 India 50 2001
Eardley et al.17 UK 105 2002
Chin18 USA 66 2003
Elwell et al.19 USA 97 2003
Liu et al.20 Taiwan 69 2005
Chow et al.21 Hong Kong 64 2006
Ocak and Eskiocack22 Turkey 49 2008
Afsar et al.23 Turkey 188 2009
Chow et al.24 Hong Kong 87 2010
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Despite the test for heterogeneity was not signiﬁcant,
we explored some of the possible sources of study heter-
ogeneity. As reported in Table 4, no heterogeneity was
found in stratiﬁed analyses.
DISCUSSION
The impaired efﬁcacy of HBV vaccine in dialysis popula-
tion has been attributed to numerous factors notably
immune compromise because of uraemia, older age,25
male gender, nutritional status,26 serological positivity for
human immunodeﬁciency virus (HIV)27 or hepatitis C
(HCV) infection,28 blood transfusion history and posses-
sion of the major histocompatibility complex aplotype
HLA-B.29 In addition, the failure to complete a full
course of HBV vaccination may cause a poor active
immunisation.30 Diabetic nephropathy is the most com-
mon cause of chronic kidney disease and diabetic
patients with normal renal function show a lower sero-
protection rate than nondiabetic patients after HBV vac-
cination.6 The link between diabetes mellitus and the
Table 2 | Vaccine schedules of
studies included in the
analysis
Authors Vaccine route
Vaccine schedule,
months
Vaccine dose,
mcg
Waite et al. Recombinant, IM 0, 1, 2, and 6 40
Fabrizi et al. Recombinant, IM 0, 1, and 2 40
Mettang et al. Recombinant, IM
(n = 14) ⁄ ID (n = 18)
0, 1, 3, and 6 40 (IM)
10 (ID)
Jha et al. Recombinant, IM 0, 1, and 2 40
Eardley et al. Recombinant, IM 0, 1, and 2 40
Elwell et al. Recombinant, IM 0, 1, and 6 40
Chin et al. Recombinant, IM 0, 1, and 6 40
Liu et al. Recombinant, IM 0, 1, 2, and 6 40
Chow et al. Recombinant, IM 0, 1, and 6 20 (n = 14)
40 (n = 26)
80 (n = 24)
Ocak et al. Recombinant, IM 0, 1, 2, and 6 40
Afsar et al. Recombinant, IM 0, 1, 2, and 6 40
Chow et al. Recombinant, IM 0, 1, and 6 40 (n = 42)
80 (n = 45)
ID, intradermal route; IM, intramuscular route.
Table 3 | Baseline characteris-
tics of studies included in the
analysis
Authors Age (years) Male, n
Time on dialysis
(months)
Waite et al. 46  14 ⁄ 59  11 49 (64%) 13.9 ⁄ 19.8
Fabrizi et al. 63.4  13.9 60 (51%) 37 ⁄ 31.1
Mettang et al. 60  10 ⁄64  11 17 (53%) NA
Jha et al. 48  1 ⁄46  15 32 (64%) NA
Eardley et al. 59 ⁄62 18 (51%) ⁄40 (57%) 18
Elwell et al. 66  14 38 (57%) NA
Chin et al. 51  2 ⁄59  2 NA NA
Liu et al. 56  14 ⁄64  8 28 (40%) 59 ⁄43
Chow et al. 43  12 33 (51%) 9.3 ⁄ 1.2
Ocak et al. 61  9 ⁄51  17 31 (63%) 28 ⁄ 32
Afsar et al. 45  14 ⁄49  8 66 (35%) 99 ⁄81
Chow et al. 59  9 ⁄60  13 51 (59%) 5.5 ⁄ 3.8
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poor and nonpersistent immunological response to HBV
vaccine in dialysis population remains controversial.
Our meta-analysis determined that patients with dia-
betes mellitus show a lower seroprotection rate to HBV
vaccine than nondiabetic patients in dialysis population.
These results were very robust as no heterogeneity
occurred in primary analysis; also, the analysis in various
subgroups yielded only minimal changes on the effect
size. This phenomenon is biologically plausible as
numerous changes in cellular and humoral immune
responses have been described in non-uraemic patients
with diabetes mellitus. As an example, the presence of
DR3 and DR7 human leucocyte antigen (HLA) alleles in
diabetic individuals has been implicated in this impaired
immunological response.31
Our ﬁndings are consistent with data from other
sources. The analysis of the FMCNA database (14546
patients with end-stage renal disease who received HBV
recombinant DNA vaccine) revealed that the OR of sero-
protection rate of HBV vaccine in DM vs. non-DM
patients with CKD was 0.83 (95% CI, 0.77; 0.89),
P = 0.002.32 A lower response rate after HBV vaccination
in diabetic vs. nondiabetic patients with CKD at predial-
ysis stage has been found in at least two surveys.33, 34
This meta-analysis is potentially limited in a number
of ways. First, as with all meta-analyses, this study has
the potential limitation of publication bias. Negative tri-
als are less likely to be published – we postulated that
the authors who found a statistical association between
diabetes mellitus and response rate to HBV vaccine
would likely be to comment on such a ﬁnding in pub-
lished manuscripts, whereas investigators who failed to
ﬁnd such an association would be less likely to give any
comment. This is of particular concern, given that the
evaluation of vaccine response according to diabetes
mellitus was not a primary objective of most studies (11
of 12, 92%) included in our analysis. To limit the possi-
ble effect of publication bias, we used several strategies
for identifying studies to include published and unpub-
lished studies. Inclusion criteria, established a priori,
were chosen to increase the likelihood that high-quality
studies would be included. Secondly, there was in our
studies incomplete information about nutritional status,
HIV ⁄HCV infection, serum haemoglobin concentration,
erythropoietin use or adequacy of dialysis. However, the
link between these parameters and seroresponse to HBV
vaccine is still controversial in dialysis population. In
their multiple logistic regression model, Chin18 found
that DM was a signiﬁcant and independent predictor of
failure to seroconvert after vaccination against HBV (OR,
3.4; 95% CI, 1.3–9.0; P = 0.01). Finally, we have made
mostly a meta-analysis of observational studies and it is
clear that a meta-analysis of randomised clinical trials is
provided with better accuracy and reliability. The low
heterogeneity found in primary and stratiﬁed analyses,
the absence of publication bias and the good number
(n = 1002) of patients available for our analysis
strengthen our data.
Various approaches have been suggested in order to
improve the response rate to hepatitis B vaccine in dialy-
sis population including increased vaccine doses14 or
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Figure 1 | Response rate to HB vaccine: diabetic vs. non-
diabetic patients (Galbraith plot).
Table 4 | Pooled odds ratio
(OR) of failure to respond to
vaccine (diabetic vs. nondia-
betic patients) in various sub-
groups of interest
Random-effects model
OR (95% CI) Q (P) I2
All studies (n = 12) 0.52 (0.38; 0.71) 12.97 (0.295) 22.9
I.M. patients (n = 11) 0.53 (0.38; 0.74) 12.9 (0.23) 30.2
Prospective studies (n = 9) 0.58 (0.41; 0.83) 5.9 (1.0) 0
HD patients (n = 8) 0.60 (0.41; 0.87) 8.09 (0.32) 25.9
Studies from western world (n = 6) 0.54 (0.33; 0.90) 6.9 (0.2) 42.2
Meta-analysis: hepatitis B vaccine and diabetes mellitus in dialysis
Aliment Pharmacol Ther 2011; 33: 815–821 819
ª 2011 Blackwell Publishing Ltd
shots; recent evidence has shown efﬁcacy and safety of
intradermal administration of recombinant vaccine
towards HBV35–37 in dialysis population. HBV vaccine
has been given to uraemic patients not yet requiring regu-
lar dialysis.33, 34 Numerous vaccine adjuvants have been
recommended, such as interferon, interleukin and eryth-
ropoietin, among others. The Centers for Disease Control
(CDC)38 currently recommends that dialysis patients
receive by intramuscular route double doses (20 mcg · 2)
at 0, 1, 2 and 6 months with regular monitoring of anti-
body levels to ensure that antibody concentrations remain
above the protective level of 10 mIU ⁄mL. There is no
evidence that the various approaches to improve HBV
vaccination response rates have an effect in diabetics on
dialysis. Studies on vaccination schedules with adapted
vaccine doses or shots, intradermal administration of
recombinant vaccine or use of vaccine adjuvants are
under way among dialysis patients with diabetes mellitus.
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